NCT07130565 Pan-Amyloid PET/CT in Various Amyloid-Related Disease
| NCT ID | NCT07130565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University |
| Condition | Amyloid |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2028-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-11-01 with a primary completion date of 2028-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.
Eligibility Criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated cardiac amyloidosis (supporting evidence may include MRI, CT, serum markers and pathology report); (iii) patients who had scheduled Pan-Amyloid PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-CA lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07130565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Amyloid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07130565 currently recruiting?
Yes, NCT07130565 is actively recruiting participants. Contact the research team at dreamadam@126.com for enrollment information.
Where is the NCT07130565 trial being conducted?
This trial is being conducted at Hefei, China, Tianjin, China.
Who is sponsoring the NCT07130565 clinical trial?
NCT07130565 is sponsored by Tianjin Medical University. The trial plans to enroll 500 participants.